Falls: a marker of preclinical Alzheimer disease: a cohort study protocol

Rebecca M Bollinger,1,2 Audrey Keleman,1,2 Regina Thompson,2 Elizabeth Westerhaus,2 Anne M Fagan,2 Tammie LS Benzinger,3 Suzanne E Schindler,2,4 Chengjie Xiong,4 David Balota,2,5 John C Morris,2 Beau M Ances,2,5 Susan L Stark1

ABSTRACT

Introduction  Progression to symptomatic Alzheimer disease (AD) occurs slowly over a series of preclinical stages. Declining functional mobility may be an early indicator of loss of brain network integration and may lead to an increased risk of experiencing falls. It is unknown whether measures of functional mobility and falls are preclinical markers of AD. The purpose of this study is to examine (1) the relationship between falls and functional mobility with AD biomarkers to determine when falls occur within the temporal progression to symptomatic Alzheimer disease, and (2) the attentional compared with perceptual/motor systems that underlie falls and functional mobility changes seen with AD.

Methods and analysis This longitudinal cohort study will be conducted at the Knight Alzheimer Disease Research Center. Approximately 350 cognitively normal participants (with and without preclinical AD) will complete an in-home visit every year for 4 years. During each yearly assessment, functional mobility will be assessed using the Performance Oriented Mobility Assessment, Timed Up and Go, and Timed Up and Go dual task. Data regarding falls (including number and severity) will be collected monthly by self-report and confirmed through interviews. This study will leverage ongoing neuropsychological assessments and neuroimaging (including molecular imaging using positron emission tomography and MRI) performed by the Knight Alzheimer Disease Research Center. Relationships between falls and biomarkers of amyloid, tau and neurodegeneration will be evaluated.

Ethics and dissemination This study was approved by the Washington University in St Louis Institutional Review Board (reference number 201807135). Written informed consent will be obtained in the home prior to the collection of any study data. Results will be published in peer-reviewed publications and presented at national and international conferences.

Trial registration number NCT04949529; Pre-results.

INTRODUCTION

Alzheimer disease (AD) is a slowly progressive neurodegenerative disease that affects 60%–70% of the over 50 million people living with dementia worldwide.1–3 Progression to symptomatic AD occurs slowly through a series of preclinical stages marked by changes in molecular biomarkers that can be quantified by neuroimaging, cerebrospinal fluid (CSF) or plasma measures.4 Cognitively normal (CN) stage 0 individuals have no biomarker abnormalities. CN stage 1 individuals have only cerebral amyloidosis, CN stage 2 individuals have amyloidosis and neurodegeneration, and CN stage 3 individuals have evidence of amyloidosis, neurodegeneration and subtle cognitive changes.5,6 These preclinical stages of AD develop over decades and are considered clinically silent.5 However, emerging evidence suggests that impaired functional mobility (gait and balance) and subsequent falls7 may precede symptomatic cognitive impairment.5,7 Declining functional mobility and increases in falls may be due to subtle changes in attention, executive, motor and sensory processing, and may be an early indicator of loss of integration between the central (CNS) and peripheral nervous systems (PNS).8–12 Falls are a leading cause of injury, long-term disability, premature institutionalisation and injury-related death in older individuals.13,14 Individuals with symptomatic AD have a 60%–80% increased risk of falling.
and those who fall are five times more likely to be institutionalized than similar individuals who do not fall.13 15 A knowledge gap exists as to whether functional mobility and falls could serve as preclinical markers of AD.16

We previously demonstrated that falls occur at higher rates during the preclinical phase of AD, and the mechanisms that underlie the deterioration of cognitive function were associated with declines in gait and balance necessary for functional mobility.9 Functional connections in the brain, referred to as resting state functional connectivity (rs-fc), decrease in symptomatic AD.17 We observed a decrease in rs-fc for CN individuals with preclinical AD in the dorsal attention network (DAN), a set of brain regions involved in attentional control and planning.17 Functional connections both within the DAN and across other resting state networks (RSNs) may affect one’s functional mobility when attempting to navigate home and community environments. While self-reported performance is obtained from CN individuals (with and without preclinical AD), performance-based measures of everyday function are not recorded. Additional research is therefore needed to examine the relationship between functional mobility/falls and rs-fc, especially for CN individuals with preclinical AD.

For this longitudinal observational study, we will evaluate CN individuals (with and without preclinical AD) at baseline who are currently undergoing comprehensive clinical, neuropsychological and biomarker evaluations at the Knight Alzheimer Disease Research Center (Knight ADRC). Annually, we will conduct an in-home evaluation of fall risks and functional mobility and prospective ascertainment of falls. Comparisons of objective assessments of functional mobility will be performed with regard to measures of brain pathology (using in vivo markers of cerebral amyloidosis and neurodegeneration) to allow us to characterize when changes in falls and functional mobility occur during the preclinical stages of AD. We will also examine attentional compared with perceptual/motor systems that underlie falls and functional mobility in preclinical AD. Falls and functional mobility measures could serve as innovative, inexpensive screening tools to identify individuals at increased risk for progression to symptomatic AD. This may have important implications for the timing of interventions in secondary prevention trials in AD and for the development of more precise, effective treatments for individuals with AD.18

**METHODS AND ANALYSIS**

**Participants**

In this longitudinal cohort study, community-dwelling older adults will be recruited from an existing cohort followed by the Knight ADRC. Inclusion criteria for this study are as follows: ≥65 years of age, CN (Clinical Dementia Rating (CDR) score of 0, indicating no dementia), and collection of biomarkers (CSF) and/or neuroimaging (positron emission tomography (PET) and/or MRI) within 2 years of study enrolment. Recruitment procedures for the Knight ADRC have been published previously.20

**Recruitment**

Participants (N=350) will be recruited for in-home visits near the time of their annual clinical assessment at the Knight ADRC. Knight ADRC staff will approach participants who meet inclusion criteria about their interest regarding this study. If interested, potential participants will be referred to a study team member who will provide a detailed description of the study procedures and invite the individual to participate. Letters will also be sent to all eligible individuals to invite them to participate in this study. Written, informed consent will be obtained in the home prior to the collection of any study data. This study was approved by the Institutional Review Board at Washington University in St. Louis (reference number: 201807135).

**Study procedures**

All Knight ADRC participants in principle complete longitudinal clinical and neuropsychological assessment and biomarker studies of biofluids (blood, CSF) and neuroimaging (amyloid PET, structural and functional MRI; see grey boxes in figure 1). For this study, participants additionally will receive an annual in-home visit and will report falls prospectively for the duration of the study (see blue boxes in figure 1).

**Knight ADRC Clinical Assessment**

Knight ADRC participants complete an annual clinical assessment battery administered by an experienced clinician using a standardised protocol. During this visit, the CDR assesses the participant’s cognitive and functional performance: 0=CN, 0.5=very mild symptomatic AD, 1=mild symptomatic AD, 2=moderate symptomatic AD or 3=severe symptomatic AD.19 A neurological examination is performed for each participant. At enrolment, participants must have a CDR=0.

**Knight ADRC Psychometric/Neuropsychological Assessments**

Participants complete a standard 2-hour psychometric battery within 2 weeks of their annual clinical assessment by an experienced psychometrist and board-certified neurologist blinded to the participant’s preclinical AD status.22 A sensitive composite of attentional and executive control tests that is highly predictive of the transition from healthy ageing to symptomatic AD23–25 will be compared with functional mobility and fall measures.22

**Biomarker acquisition/brain neuropathology assessments**

Participants also complete PET scans27 and MRI28 and undergo CSF and blood collection29 30 at the Knight ADRC every 3 years.

**PET imaging**

PET imaging will be conducted on a 3T Siemens Biograph mMR hybrid scanner using the radiotracer [18F] Florbetapir (AV45) to detect in vivo presence of amyloid in...
the brain. Quantitative image analysis will be performed using a standard amyloid imaging analysis protocol that uses FreeSurfer regions of interest (ROIs; Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA). Regional standardised uptake value ratios (SUVRs) will be obtained using the cerebellum as the reference region.

**Structural MRI**

High-resolution structural MRI scans will be acquired using a T1-weighted magnetisation-prepared rapid gradient echo sequence to analyse brain volumetrics. Images will be subsequently analysed using standard procedures developed at the Knight ADRC using FreeSurfer to delineate brain regions, including cortical and subcortical areas, typically affected by AD.

**Functional MRI/network dysfunction**

During the MRI scan, rs-fc scans will be obtained using a gradient spin-echo sequence. Participants will be instructed to fixate on a visual crosshair and not to fall asleep. Rs-fc pre-processing and post-processing will be performed using standardised, in-house methods. In preparation for correlation analysis, data will be spatially smoothed with a 6mm full-width at half maximum Gaussian blur. Then, temporal low-pass filtering (f<0.1 Hz) will be applied to the time series of each voxel. Finally, spurious variance will be removed using linear regression for (1) six parameters generated from head motion correction, (2) the whole brain signal and (3) signals from ventricular and cerebral white matter. An ROI-based analysis consisting of 298 seeds will be performed with a Pearson's correlation coefficient computed between pairwise ROI time courses across all areas within RSNs. From these 298 seeds, correlation matrices will be generated for each participant. For the 13 RSNs, correlation coefficients across ROI pairs within a network will be averaged to form a composite score. Based on average matrices, both intra-network (diagonal) and inter-network (off diagonal) composite scores will be generated.

**CSF biomarkers**

CSF will be collected at approximately 08:00 following overnight fasting. About 20–30 mL of CSF is collected, centrifuged briefly at low speed, aliquoted into polypropylene tubes and then stored at −80°C. Aβ40, Aβ42, total tau (tTau) and tau phosphorylated at 181 (pTau181) are measured by chemiluminescent enzyme immunoassay using a fully automated platform (LUMIPULSE G1200, Fujirebio) according to the manufacturer's specifications. APOE genotype will be determined by genotyping rs7412 and rs429358 using Taqman genotyping technology as described previously.

**Preclinical AD staging**

Biomarker positivity will be defined by correlating biomarker values at baseline with the risk of developing AD symptoms over time. The derivation of the biomarker cut-offs will be independent of the data collected in this project. Of note, CSF markers of tauopathy (pTau181) and neurodegeneration (tTau) are extremely highly correlated (r~0.96), so further stratification of stage by tauopathy would not be meaningful. Participants will be classified as follows: CN if measures of amyloid, neurodegeneration and episodic memory are normal; stage 1 if only measures of amyloid are abnormal by CSF Aβ42/Aβ40 or amyloid PET mean cortical SUVRs (which are highly concordant); stage 2 if only measures of amyloid and neurodegeneration (by CSF tTau) are abnormal; and stage 3 if measures of amyloid, neurodegeneration and episodic memory are abnormal.

**Annual in-home visit**

An occupational therapist (OT), blinded to participants’ preclinical AD status, will complete a 120–180 min in-home visit annually for 4 years. The OT will conduct assessments related to the PNS as well as in-home functional mobility and recognised fall covariates (tables 1 and 2). Although the annual visit is typically completed in one session, it will be completed over two sessions if needed due to participant fatigue and/or request. Participants

---

**Figure 1** Research design overview. Measures of interest collected by the Knight Alzheimer Disease Research Center (Knight ADRC) will be available at no cost. In-home assessments will be collected annually, and falls will be monitored prospectively.
**Table 1** Knight ADRC and in-home assessments

| Construct                        | Measure                                           | Description                                                                                      |
|---------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------------------|
| **Central nervous system**      | **Attentional/executive control composite derived** | Colour naming of congruent (eg, red), neutral (eg, deep) or incongruent (eg, blue) word        |
|                                 | Stroop colour naming task<sup>51</sup>           | Naming direction of an arrow with a keypress that is spatially consistent or inconsistent with the location of the arrow including congruent and incongruent positioning |
|                                 | Simon task<sup>52</sup>                          |                                                                                                 |
|                                 | Attentional switching task<sup>53</sup>           | Switching every other trial between making odd-even decisions and consonant-vowel decisions on bivalent stimuli (eg, B14) |
| **Peripheral nervous system**   | **Standing, balance and vestibular function**    | Centre of pressure path will be measured using Balance Tracking System (BTrackS)                |
| **Lower extremity strength and function** | 30-second chair stand test<sup>55</sup>         | A score below the norm will be considered indicative of decreased lower extremity strength and function |
|                                 | Handheld dynamometer<sup>56</sup>               | Minimal change in the peak torque value for lower extremity strength will be measured           |
| **Grip strength**               | Handheld dynamometer<sup>57</sup>               | Pounds of force will be captured for grip strength                                              |
| **Vision**                      | Early Treatment Diabetic Retinopathy Study (ETDRS) test<sup>58</sup> | Visual acuity score; number of correct letters read                                             |
|                                 | Pelli-Robson test<sup>59</sup>                   | Contrast sensitivity; letter-by-letter                                                          |
| **Sensation**                  | Tuning fork, sharp<sup>60</sup>                  | 8-item questionnaire and sensation testing (vibration (feet) and sharp (arms and legs))         |
| **Functional mobility**         | **Performance-Oriented Mobility Assessment (POMA)<sup>61</sup>** | A task-oriented assessment of 9 balance tasks and 7 items to assess gait                       |
| **Gait speed**                  | Timed Up and Go (TUG) test<sup>62</sup>          | Timed task of standing up, walking 3m, turning, walking back and sitting down                   |
| **Dual-task gait**              | Timed Up and Go Cognitive (TUG<sub>cog</sub>)<sup>63</sup> | TUG test while reciting serial 3s with subtractions from various points                          |
| **Dual-task gait**              | Timed Up and Go Manual (TUG<sub>man</sub>)<sup>64</sup> | TUG test while carrying a glass of water                                                        |
| **Additional assessments**      | **Alcohol abuse**                                | 10-Item interview                                                                                |
| **Depression**                  | Patient Health Questionnaire (PHQ-9)<sup>65</sup> | 10-Item questionnaire to assess frequency of symptoms; 0–27 points                             |
| **Geriatric Depression Scale—Short Form (GDS-SF)<sup>67</sup>** | 15-Item questionnaire; 0–15 points               |
| **Urinary incontinence**        | Frequency and type<sup>68</sup>                  | Short questionnaire of frequency and type (stress, urge or other)                               |
| **Pain**                        | Self-report<sup>69</sup>                          | Pain scale from 12-item Short Form Survey                                                       |
| **Medication**                  | Medication review<sup>*</sup>                     | Medications and dosages                                                                          |
| **Functional capacity**         | Older Adults Resources and Services Activities of Daily Living (OARS ADL) scale<sup>70</sup> | Ability to perform 14 activities; 0–2 scale, higher scores indicate greater independence       |
| **Functional performance**      | Performance Assessment of Self-Care Skills (PASS)<sup>71</sup> | Evaluates independence, safety, and adequacy with shopping, chequebook balancing and medication management |
| **Falls behaviour**             | Falls Behavioural Scale for Older People (FaB)<sup>72</sup> | 30-Item questionnaire; rated from 1 (least protective) to 4 (most protective) behaviours to prevent falls |
| **Self-efficacy**               | Falls Efficacy Scale—International (FES-ISF)<sup>73</sup> | 7 daily activities; rated from 1 (not at all) to 4 (very concerned) about falling during specific activities |
| **Home hazards**                | Westmead Home Safety Assessment (WeSHA)<sup>74</sup> | Rates 72 environmental home hazards as hazard/no hazard                                         |
| **Olfaction**                   | University of Pennsylvania Smell Identification Test (UPSIT)<sup>75</sup> | 40-Item smell identification test; 0–40 points                                                    |
| **Hearing**                     | Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S)<sup>76</sup> | 10-Item questionnaire to screen for hearing impairment; 0–40 points                             |
|                                 | Brief Hearing Test                                | Screening tone test at varying frequencies                                                     |

<sup>*</sup>Collected at the Knight ADRC.
Knight ADRC, Knight Alzheimer Disease Research Center.
will receive a report with their results from the home visit and fall risk assessment based on established fall risk cut-off scores.38

**Monthly fall reporting**

Participants will report falls prospectively via automated call or email every month for 4 years using the gold standard for fall reporting, including daily calendar journals, fall interviews and monetary compensation for reporting.39 Participants will also receive a standardised fall report form to record the time and location of a fall, nature of the fall environment, specific activity at the time of the fall and any somatic complaints that proceeded the fall.40 If a participant reports a fall, an interviewer blinded to preclinical AD status will call the participant to complete a fall interview to verify the fall, defined as an unintentional movement to the floor, ground or an object below knee level.41 42 The rate (number) and severity (calculated with a standardised algorithm from medical records and participant report) of falls will be generated.13 The falls severity score will be quantified using a previously published algorithm: no falls (0), 1 fall without serious injury (1), any fall with minor injury or more than 1 fall (2), and major injury requiring hospitalisation (3).14

**Statistical analysis plan for the primary aim**

We will examine the distributions of falls (number and severity) over a 1-year follow-up window and baseline functional mobility scores across the preclinical stages of AD (0, 1, 2 and 3),4 with appropriate transformations as needed. Falls severity scores across preclinical stages will be compared using analysis of covariance models.44 Similar analyses will be conducted to compare each of the functional mobility measures across the preclinical stages of AD. We will implement adequate approaches (eg, Benjamini-Hochberg false discovery procedure45 to control for the overall type I error rate due to multiple

### Table 2 Fall covariate composite score variables

| Construct          | Measure                                                                 | Description                                                                 | Fall risk cut-off |
|--------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------|
| Vision             | Early Treatment Diabetic Retinopathy Study (ETDRS) test58 Pelli-Robson test55 | Visual acuity score; number of correct letters read                        | ≤12               |
|                    |                                                                        | Contrast sensitivity; letter-by-letter                                       | <36 letters       |
| Alcohol abuse      | Short Michigan Alcoholism Screening Test—Geriatric Version (SMAST-G)65  | 10-Item interview                                                          | ≥2                |
| Depression         | Geriatric Depression Scale—Short Form (GDS-SF)57*                      | 15-Item questionnaire; 0-15 points                                           | >4                |
| Urinary incontinence | Frequency and type68                                                   | Short questionnaire of frequency and type (stress, urge or other)            | ≥weekly urge incontinence |
| Pain               | Self-report59                                                           | Pain scale from 12-item Short Form Survey                                   | ≥moderate         |
| Medication         | Medication review*                                                     | Medications and dosages                                                     | ≥4 medications    |
| Functional capacity | Older Adults Resources and Services Activities of Daily Living (OARS ADL) scale70 | Ability to perform 14 activities; 0-2 scale, higher scores indicate greater independence | >4                |
| Previous falls     | Previous falls38                                                        | Total falls in the past 12 months, self-report                              | >0                |
| Home hazards       | Westmead Home Safety Assessment (WeSHA)74                              | Rates 72 environmental home hazards as hazard/no hazard                     | ≥4 hazards        |
| Self-efficacy      | Falls Efficacy Scale—International (FES-ISF)73                         | 7 daily activities; rated from 1 (not at all) to 4 (very concerned) about falling during specific activities | >10               |

*Collected at the Knight ADRC.

**Statistical analysis plan**

Data will be entered into Research Electronic Data Capture (REDCap),43 a secure, web-based application, and analysed using SAS, V.9.4 (SAS Institute). Differences in baseline characteristics across groups will be compared using appropriate statistics (χ² test, Student’s t-test or Mann-Whitney U test). Composites and cut-offs will be calculated as described in the Methods and analysis section (see table 2). Models for analysing AD biomarkers and cognition will include age, gender, fall risk composite score, APOE status (at least APOE ε4 allele), as well as possible interactions among study variables. Models will be implemented using PROC GLM or PROC MIXED/SAS.

**Measures**

An overview of the assessments collected at the Knight ADRC and annual in-home visits, including CNS and PNS measures, functional mobility, additional covariates of interest and fall covariates, for this study are listed in tables 1 and 2.
outcome variables (number and severity of falls, functional mobility) tested in this aim.

We will also jointly model the longitudinal falls severity score and the time-to-symptom onset of AD (defined as the first time a participant receives a CDR >0) using general linear mixed effects models. For modelling the risk of developing AD, we will use the semiparametric Cox proportional hazards model. To address the association between change in falls and the risk of developing symptomatic AD, we will implement joint models.

Statistical analysis plan for the secondary aim
We will test a hypothesised model of attentional compared with perceptual/motor systems underlying falls in preclinical AD using structural equation models (SEMs) on cross-sectional data. The structural model will include the estimation of path coefficients among various latent constructs including brain neuropathology, network dysfunction, PNS abnormalities and falls. We will fit and compare various SEMs for their goodness-of-fit through standard statistics using multiple models.

Sample size calculations
Primary aim
To examine the relationship between falls, functional mobility and AD, we will enrol 350 older adults from the Knight ADRC. Based on the distribution of CN participants across clinical stages in the existing Knight ADRC database, the proposed sample size will provide at least 80% statistical power to detect an effect size as small as 0.225 SD on the falls severity score between two adjacent participant groups. From the Knight ADRC database, we fitted a survival curve from baseline to the time that a CDR >0 was first rendered. We found an estimated CDR progression rate of 7.2% per year for individuals with a mean age of 75 at baseline and an expected attrition of approximately 15%. We estimate that approximately 300 participants will be assessed annually throughout the study, and approximately 75 of these individuals will progress to CDR >0 after baseline. This will provide at least 80% statistical power to detect a onefold increase in the risk of developing symptomatic AD for individuals with an increased rate of falls over time compared with those with slow or no changes in falls over time. These power computations were based on a log rank test at the 5% significance level and assumed an annual rate of 4.7% of CDR progression for individuals with slow changes in disability over time.

Secondary aim
We also tested non-zero path coefficients that link the latent constructs of network dysfunction with attentional compared with perceptual/motor systems, and to impaired functional mobility and falls. The proposed sample provides at least 80% statistical power to detect each path coefficient.

Participants and public involvement
Participants and the public were not involved in the design, conduct, reporting or dissemination plans of our research.

Ethics and dissemination
This study was approved by the Washington University in St. Louis Institutional Review Board (reference number 201807135). Written informed consent will be obtained in the home prior to the collection of any study data. Participants may withdraw from the study at any time. Results will be published in peer-reviewed publications and presented at national and international conferences.

DISCUSSION
Changes in functional mobility and an increase in falls may be an early indicator of preclinical AD. Underlying deviations in functional connectivity may assist in identifying brain RSNs that are affected and lead to falls. Measures of everyday function are not currently included in the evaluation of CN individuals with preclinical AD. To examine these relationships, this study will assess the number and severity of falls, functional mobility (gait and balance), and changes in functional connections (rs-fc) within and across RSNs in a sample of community-dwelling older adults. This will allow us to characterise when changes in falls and functional mobility occur during the preclinical stages of AD as well as potential mechanisms.

The strengths of this study include access to a large, well-characterised cohort of community-dwelling older adults at the Knight ADRC who are enthusiastic about participating in studies. Another strength includes a comprehensive in-home evaluation of a participant’s fall risks and functional mobility and the ability to share results with each participant.

Although the strengths are promising, there are a few limitations to this study. First, older adults may not be compliant with fall monitoring over time. The OTs will call participants to obtain fall information if participants do not want to complete the fall monitoring via automated call or email. Lastly, it may be difficult to differentiate falling from ageing-related phenotypes such as frailty. We will collect information on covariates, including comorbid conditions and other fall risk factors, test these relationships in individuals without preclinical AD and control for these covariates in statistical analyses.

This study is designed to examine the relationship between falls and functional mobility and underlying attentional compared with perceptual/motor systems in preclinical stages of AD. The findings will enhance our understanding of the systemic manifestations of AD and may identify falls as a previously unknown risk factor for developing preclinical AD. If successful, this study can potentially inform the timing of interventions in secondary prevention trials in AD as well as the
development of more precise, effective treatments for individuals at risk for progression to symptomatic AD.18

**Twitter** Susan L Stark @PEPLaboratory

**Acknowledgements** We would like to thank the Knight Alzheimer Disease Research Center staff and all of our participants for making this study possible.

**Contributors** The study concept and design was conceived by SLS, BMA, CX, DB and JCM. Patient safety protocols and IRB compliance will be managed by EW, RT and RMB. Recruitment and data collection will be conducted by RMB, RT and AK. Analysis will be performed by AMF, TLSB, SES and CX. The first draft of the protocol was prepared by BMA and SLS. All authors provided edits and approved the final version of the protocol.

**Funding** This work was supported by the National Institute on Aging (1 R01 AG057680-01A1), the Healthy Aging and Senile Dementia Program Project (P01 AG033991), the Knight Alzheimer Disease Research Center (P30 AG066444), Antecedent Biomarkers for AD: the Adult Children Study (P01 AG062276), the Paula C. and Rodger O. Riney Fund, and the Daniel J. Brennan MD Fund.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs** Rebecca M Bollinger http://orcid.org/0000-0002-1931-8372 Audrey Kelman http://orcid.org/0000-0003-1025-3100 Anne M Fagan http://orcid.org/0000-0002-5383-0214 Tammie LS Benzinger http://orcid.org/0000-0002-8114-0552 Suzanne E Schindler http://orcid.org/0000-0002-1680-1465 John C Morris http://orcid.org/0000-0001-9820-5618 Beau M Ances http://orcid.org/0000-0003-3862-7397 Susan L Stark http://orcid.org/0000-0002-2816-7158

**REFERENCES**

1 World Health Organization. Fact sheets: dementia. World Health organization, 2020. Available: https://www.who.int/en/news-room/fact-sheets/detail/dementia2020 [Accessed 21 Sep 2020].

2 Patterson C. Worldwide Alzheimer report 2018: the state of the art of dementia research: new frontiers. London: Alzheimer Disease International, 2018.

3 Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122–31.

4 Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280–92.

5 Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:796–804.

6 Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957–65.

7 Jack CR, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539–47.

8 Egenberger P, Wolf M, Schumann M, et al. Exergame and balance training modulate prefrontal brain activity during walking and enhance executive function in older adults. Front Aging Neurosci 2016;6:66.

9 Stark SL, Roe CM, Grant EA, et al. Preclinical Alzheimer disease and risk of falls. Neurology 2013;81:437–43.

10 Montero-Odasso M, O tener-Amaoko A, Speechley M, et al. The motor signature of mild cognitive impairment: results from the gait and brain study. J Gerontol A Biol Sci Med Sci 2014;69:1415–21.

11 Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer’s disease. Alzheimers Dement 2015;11:70–98.

12 Sheridan PL, Hausdorff JM. The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;24:125–37.

13 Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701–7.

14 Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997;337:1279–84.

15 Morris JC, Rubin EH, Morris EJ, et al. Senile dementia of the Alzheimer’s type: an important risk factor for serious falls. J Gerontol 1987;42:412–7.

16 McGough EL, Lin S-Y, Belza B, et al. A scoping review of physical performance outcome measures used in exercise interventions for older adults with Alzheimer disease and related dementias. J Geriatr Phys Ther 2019;42:28–47.

17 Brier MR, Thomas JB, Snyder AZ, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer’s disease progression. Neuroimage 2012;63:8890–9.

18 Ansai JH, Andrade LPd, Masse FAA, et al. Risk factors for falls in older adults with mild cognitive impairment and mild Alzheimer disease. J Geriatr Phys Ther 2019;42:E116–21.

19 Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412–4.

20 Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol 2019;76:264–73.

21 Berg L, McKeel DW, Miller JP, et al. Neuropathological indexes of Alzheimer’s disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993;50:349–58.

22 Storandt M, Hill RD. Very mild senile dementia of the Alzheimer type. II. psychometric test performance. Arch Neurol 1989;46:385–6.

23 Duchek JM, Balata DA, Thomas JB, et al. Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. Neuropsychology 2013;27:516–28.

24 Aschenbrenner AJ, Balata DA, Fagan AM, et al. Alzheimer disease cerebrospinal fluid biomarkers moderate baseline differences and predict longitudinal change in attentional control and episodic memory composites in the adult children study. J Int Neuropsychol Soc 2015;21:573–83.

25 Aschenbrenner AJ, Balata DA, Tse C-S, et al. Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology 2015;29:368–81.

26 Su Y, D’Angelo GM, Vlassenko AG, et al. Quantitative analysis of PIB-PET with FreeSurfer ROIs. PLoS One 2013;8:e73377.

27 Joshi AD, Pontecorvo MJ, Clark CV, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med 2012;53:378–84.

28 Wang L, Benzinger TL, Hassenstab J, et al. Spatially distinct atrophy is linked to [a]-amyloid and tau in preclinical Alzheimer disease. Neurology 2015;84:1254–60.

29 Carrillo MC, Blackwell A, Hampil H, et al. Early risk assessment for Alzheimer’s disease. Alzheimers Dement 2009;5:182–96.

30 Craig-Schapiro R, Fagan AM, Holtzman DM, et al. Biomarkers of Alzheimer’s disease. Neurobiol Dis 2009;35:128–40.

31 Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–55.

32 Shulman GL, Pope DLW, Astafyev SV, et al. Right hemisphere dominance during spatial selective attention and target detection occurs outside the dorsal frontoparietal network. J Neurosci 2010;30:3640–51.

33 Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512–9.

34 Kaplow J, Vandijck M, Gray J, et al. Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status. Alzheimers Dement 2020;16:144–52.

35 Crucchera C, Kauwe JS, Meda K, et al. Snps associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer’s disease. PLoS Genet 2010;6:e1001101.
Bollinger RM, et al. BMJ Open 2021;11:e050820. doi:10.1136/bmjopen-2021-050820

36 Soldan A, Pettigrew C, Fagan AM, et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. *Neurology* 2019;92:e1567–79.

37 Mishra S, Gordon BA, Su Y, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. *Neuroimaging* 2017;16:171–8.

38 Lusardi MM, Fritz S, Middleton A, et al. Determining risk of falls in community dwelling older adults: a systematic review and meta-analysis using posttest probability. *J Geriatr Phys Ther* 2017;40:1–36.

39 Lamb SE, Jerstad-Stein EC, Hauer K, et al. Development of a common outcome data set for fall injury prevention trials: the prevention of falls network Europe consensus. *J Am Geriatr Soc* 2005;53:1618–22.

40 Lach HW, Reed AT, Arfenk CL, et al. Falls in the elderly: reliability of a classification ed. New York: The Guilford Press, 1995.

41 Stark SL, Roe C, Grant E. International Conference on Alzheimer's Disease, 2011. *Alzheimer's disease* 2019;92:e1567–79.

42 Stark S, Somerville E, Conte J, Keglovits M, et al. Feasibility trial of tailored home modifications: process outcomes. *Am J Occup Ther* 2018;72:7201205001–20.

43 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81.

44 Milliken GA, Johnson DE, eds. *Analysis of Messy Data*. New York: Chapman & Hall/CRC, 2001.

45 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Methodol* 1995;57:289–300.

46 Diggie P, Liang K-Y, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press, 1994.

47 Jacqmin-Gadda H, Commenges D, Dartigues J-F. Random change point model for joint modeling of cognitive decline and dementia. *Biometrica* 2004;91:567–81.

48 De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival time. *Biometrics* 1994;50:1003–14.

49 Kline RB. *Principles and practice of structural equation modeling*. New York: The Guilford Press, 2015.

50 Stark SL, Roe C, Grant E. Risk of falls in older adults with preclinical Alzheimer's disease. Paris, France: Alzheimer’s Association International Conference on Alzheimer’s Disease, 2011.

51 MacLeod CA. The stroop task: The “gold standard” of attentional measures. *J Exp Psychol: Human* 1992;121:12–14.

52 Simon JR. Reactions toward the source of stimulation. *J Exp Psychol* 1969;81:174–6.

53 Schmitter-Edgecombe M, Langill M. Costs of a predictable switch between simple cognitive tasks following severe closed-head injury. *Neuropsychology* 2006;20:675–84.

54 O’Connor SM, Baweja HS, Goble DJ. Validating the BTrackS balance plate as a low cost alternative for the measurement of sway-induced center of pressure. *J Biomech* 2016;49:4142–5.

55 Rikli RE, Jones CJ. Functional fitness normative scores for community-residing older adults, ages 60-94. *J Aging Phys Act* 1999;7:162–81.

56 O’Shea SD, Taylor NF, Paratz JD. Measuring muscle strength for people with chronic obstructive pulmonary disease: retest reliability of hand-held dynamometry. *Arch Phys Med Rehabil* 2007;88:32–6.

57 Bohannon RW. Hand-grip dynamometry predicts future outcomes in aging adults. *J Geriatr Phys Ther* 2008;31:3–10.

58 Ferris FL, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. *Am J Ophthalmol* 1982;94:91–6.

59 Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. *Clin Vis Sci* 1988;2:187–99.

60 Kästnerbauer T, Sauseng S, Brath H, et al. The value of the Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. *Diabet Med* 2004;21:563–7.

61 Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. *J Am Geriatr Soc* 1986;34:119–26.

62 Podsiadlo D, Richardson S. The timed ‘Up & Go’: a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc* 1991;39:142–8.

63 Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. *Phys Ther* 2000;80:896–903.

64 Lundin-Olsson L, Nyberg L, Gustafson Y. Attention, frailty, and falls: the effect of a manual task on basic mobility. *J Am Geriatr Soc* 1998;46:758–61.

65 Blow FC, Brower KJ, Schulenberg JE. The Michigan alcoholism screening test – geriatric version (MAST-G): a new elderly-specific screening instrument. *Alcohol Clin Exp Res* 1992;16:372.

66 Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study, primary care evaluation of mental disorders. patient health questionnaire. *JAMA* 1999;282:1737–44.

67 Sheikh J, Yesavage J. Geriatric depression scale (GDS): recent evidence and development of a shorter version. *Clin Gerontol* 1986;5:165–73.

68 Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? *J Am Geriatr Soc* 2000;48:721–5.

69 Gandek B, Ware JE, Aaronson NK, et al. Cross-Validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International quality of life assessment. *J Clin Epidemiol* 1998;51:1171–8.

70 Fillenbaum GG, Smyer MA. The development, validity and reliability of the OARS multidimensional functional assessment questionnaire. *J Gerontol* 1981;36:428–34.

71 Rogers J, Holm M. Performance assessment of self-care skills. *unpublished performance test*. Pittsburgh, PA: University of Pittsburgh, 1989.

72 Clemson L, Cumming RG, Heard R. The development of an assessment to evaluate behavioral factors associated with falling. *Am J Occup Ther* 2003;57:380–8.

73 Kempen GJLM, Yardley L, van Haastregt JCM, et al. The short FES-I: a shortened version of the falls efficacy scale-international to assess fear of falling, *Age Ageing* 2008;37:45–50.

74 Clemson L, Roland M, Cumming RG. Types of hazards in the homes of elderly people. *Occup Ther J Res* 1997;17:200–13.

75 Doty RL, Shamar P, Kimmelman CP, et al. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. *Laryngoscope* 1984;94:176–8.

76 Ventry IM, Weinstein BE. Identification of elderly people with hearing problems. *ASHA* 1983;25:37–42.